<DOC>
	<DOCNO>NCT00448396</DOCNO>
	<brief_summary>To evaluate effect patupilone pharmacokinetics warfarin patient advanced malignancy .</brief_summary>
	<brief_title>Evaluate Effects Patupilone Pharmacokinetics Pharmacodynamics Warfarin Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion Age ≥ 18 year age Life expectancy ≥3 month Histologically document advanced solid tumor progress standard systemic therapy standard systemic therapy exist Agents contain warfarin heparin must discontinue 7 day prior enrollment study Exclusion criterion History of/or active bleeding disorder Known hypersensitivity warfarin relate compound The use vitamin K Central line require anticoagulant maintenance The use agent contain warfarin heparin Known diagnosis human immunodeficiency virus ( HIV ) infection , hepatitis Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>EPO</keyword>
	<keyword>Patupilone</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Advanced malignancy</keyword>
</DOC>